Literature DB >> 15962390

Relationship between the downregulation of HLA class I antigen and clinicopathological significance in gastric cancer.

Yu-Qing Shen1, Jian-Qiong Zhang, Feng-Qing Miao, Jian-Min Zhang, Qin Jiang, Hao Chen, Xiang-Nian Shan, Wei Xie.   

Abstract

AIM: To discuss the expression of human leukocyte antigen (HLA) class I antigens in gastric cancer and correlate these with pathologic type and TNM stage.
METHODS: The expression of HLA class I antigen was detected by immunohistochemistry in 185 specimens of gastric cancer, 20 gastric cancer specimens with lymphatic metastasis and 22 controls of normal gastric mucosa using four monoclonal antibodies.
RESULTS: The expression of HLA class I antigen (B/C locus) was significantly downregulated in gastric cancer and in lymphatic metastasis than that in normal gastric mucosa (chi2=7.712, P<0.05). The expression of other HLA class I antigens was also downregulated, but the change was slight. There was no relationship between the downregulation of HLA class I antigen and that of beta2m and LMP2. The expression of HLA class I (B/C locus) was statistically correlated with pathologic stage in gastric adenocarcinoma (chi2=4.164, P<0.05).
CONCLUSION: The expression of HLA class I antigen (B/C locus) was obviously downregulated in gastric cancer and in lymphatic metastasis. This abnormal expression would provide the tumor cells with a way to avoid immunological recognition.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15962390      PMCID: PMC4315976          DOI: 10.3748/wjg.v11.i23.3628

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  15 in total

1.  Where have all the T cells gone? Mechanisms of immune evasion by tumors.

Authors:  J Finke; S Ferrone; A Frey; A Mufson; A Ochoa
Journal:  Immunol Today       Date:  1999-04

2.  Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide.

Authors:  Yuji Sato; Hiroki Shomura; Yoshiaki Maeda; Takashi Mine; Yoshie Une; Yoshinobu Akasaka; Masao Kondo; Shusaku Takahashi; Toshiki Shinohara; Kazuko Katagiri; Mika Sato; Shiori Okada; Kanae Matsui; Akira Yamada; Hideaki Yamana; Kyogo Itoh; Satoru Todo
Journal:  Cancer Sci       Date:  2003-09       Impact factor: 6.716

Review 3.  HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story.

Authors:  D J Hicklin; F M Marincola; S Ferrone
Journal:  Mol Med Today       Date:  1999-04

Review 4.  T-cell-directed cancer vaccines: mechanisms of immune escape and immune tolerance.

Authors:  G Q Phan; E Wang; F M Marincola
Journal:  Expert Opin Biol Ther       Date:  2001-05       Impact factor: 4.388

Review 5.  Implications for immunosurveillance of altered HLA class I phenotypes in human tumours.

Authors:  F Garrido; F Ruiz-Cabello; T Cabrera; J J Pérez-Villar; M López-Botet; M Duggan-Keen; P L Stern
Journal:  Immunol Today       Date:  1997-02

6.  MHC class I and II antigens on gastric carcinomas and autologous mucosa.

Authors:  A Ferron; M Perez-Ayala; A Concha; T Cabrera; M Redondo; M R Oliva; F Ruiz-Cabello; F Garrido
Journal:  J Immunogenet       Date:  1989 Aug-Oct

7.  Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer.

Authors:  Koji Kono; Akihiro Takahashi; Hidemitsu Sugai; Hideki Fujii; A Raja Choudhury; Rolf Kiessling; Yoshiro Matsumoto
Journal:  Clin Cancer Res       Date:  2002-11       Impact factor: 12.531

8.  Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression.

Authors:  T Kageshita; S Hirai; T Ono; D J Hicklin; S Ferrone
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

9.  [1990-1992 mortality of stomach cancer in China].

Authors:  Xiudi Sun; Ren Mu; Youshang Zhou; Xudong Dai; Youlin Qiao; Siwei Zhang; Xiaomei Huangfu; Jie Sun; Liandi Li; Fengzhu Lu
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2002-01

10.  HLA-DR antigen expression in intestinal-type and diffuse-type gastric carcinoma.

Authors:  M Teh; Y S Lee
Journal:  Cancer       Date:  1992-03-01       Impact factor: 6.860

View more
  7 in total

1.  Prognostic significance of HLA class I expressing in gastric carcinoma defined by monoclonal anti-pan HLA class I antibody, EMR8-5.

Authors:  Hae-Wan Lee; Soo Kee Min; Young-Su Ju; Joohon Sung; Man Sup Lim; Dae Hyun Yang; Bong Hwa Lee
Journal:  J Gastrointest Surg       Date:  2011-04-22       Impact factor: 3.452

Review 2.  The bodies fight against cancer: is human leucocyte antigen (HLA) class 1 the key?

Authors:  Arfon G M T Powell; Paul G Horgan; Joanne Edwards
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-18       Impact factor: 4.553

3.  Decreased NKG2D expression on NK cells correlates with impaired NK cell function in patients with gastric cancer.

Authors:  Hiroaki Saito; Tomohiro Osaki; Masahide Ikeguchi
Journal:  Gastric Cancer       Date:  2011-05-31       Impact factor: 7.370

4.  HLA-DQB1*03 genotype and perioperative blood transfusion are not conducive to the prognosis of patients with gastric cancer.

Authors:  Shen-Kang Zhou; Lei-Lei Yang; Rui Chen; Yong Lu; Yong-Hua Zheng
Journal:  J Clin Lab Anal       Date:  2018-04-18       Impact factor: 2.352

5.  Correlation between efficacy of PSK postoperative adjuvant immunochemotherapy for gastric cancer and expression of MHC class I.

Authors:  Gentaro Ito; Hiroaki Tanaka; Masaichi Ohira; Mami Yoshii; Kazuya Muguruma; Naoshi Kubo; Masakazu Yashiro; Nobuya Yamada; Kiyoshi Maeda; Tetsuji Sawada; Kosei Hirakawa
Journal:  Exp Ther Med       Date:  2012-04-02       Impact factor: 2.447

6.  Increased apoptosis and elevated Fas expression in circulating natural killer cells in gastric cancer patients.

Authors:  Hiroaki Saito; Seigo Takaya; Tomohiro Osaki; Masahide Ikeguchi
Journal:  Gastric Cancer       Date:  2012-11-22       Impact factor: 7.370

Review 7.  Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.

Authors:  Karthik Dhatchinamoorthy; Jeff D Colbert; Kenneth L Rock
Journal:  Front Immunol       Date:  2021-03-09       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.